AmerisourceBergen Sees Momentum Build In US Biosimilars
Key Developments Around Insulins And Interchangeability Slated For 2021
AmerisourceBergen’s senior director of biosimilars, Sean McGowan, believes that momentum is continuing to build for US biosimilars in 2021, especially with key developments involving insulins and interchangeability on the horizon.
